Abstract
As of April 15, 2020, the ongoing coronavirus disease 2019 (COVID-2019) pandemic has swept through 213 countries and infected more than 1,870,000 individuals, posing an unprecedented threat to international health and the economy. There is currently no specific treatment available for patients with COVID-19 infection. The lessons learned from past management of respiratory viral infections have provided insights into treating COVID-19. Numerous potential therapies, including supportive intervention, immunomodulatory agents, antiviral therapy, and convalescent plasma transfusion, have been tentatively applied in clinical settings. A number of these therapies have provided substantially curative benefits in treating patients with COVID-19 infection. Furthermore, intensive research and clinical trials are underway to assess the efficacy of existing drugs and identify potential therapeutic targets to develop new drugs for treating COVID-19. Herein, we summarize the current potential therapeutic approaches for diseases related to COVID-19 infection and introduce their mechanisms of action, safety, and effectiveness.
Keywords:
ACE2 blocker; Antimalaria; Antiviral: Chinese traditional medicine; COVID-19; Immunoenhancer; Monoclonal antibody; Vaccine.
Copyright © 2020 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adrenal Cortex Hormones / therapeutic use
-
Angiotensin-Converting Enzyme 2
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Anticoagulants / therapeutic use
-
Antimalarials / therapeutic use
-
Antiviral Agents / therapeutic use
-
Betacoronavirus
-
Bevacizumab / therapeutic use
-
COVID-19
-
COVID-19 Drug Treatment
-
COVID-19 Serotherapy
-
COVID-19 Vaccines
-
Chloroquine / therapeutic use
-
Coronavirus Infections / drug therapy
-
Coronavirus Infections / prevention & control
-
Coronavirus Infections / therapy*
-
Humans
-
Hydroxychloroquine / therapeutic use
-
Immunization, Passive
-
Immunoglobulins, Intravenous / therapeutic use
-
Immunologic Factors / therapeutic use
-
Interferons / therapeutic use
-
Janus Kinase Inhibitors / therapeutic use
-
Killer Cells, Natural
-
Medicine, Chinese Traditional
-
Mesenchymal Stem Cell Transplantation
-
Nitric Oxide / therapeutic use
-
Pandemics
-
Peptidyl-Dipeptidase A
-
Pneumonia, Viral / therapy*
-
SARS-CoV-2
-
Spike Glycoprotein, Coronavirus
-
Trace Elements / therapeutic use
-
Viral Vaccines / therapeutic use
-
Vitamins / therapeutic use
-
Zinc / therapeutic use
Substances
-
Adrenal Cortex Hormones
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antibodies, Monoclonal, Humanized
-
Anticoagulants
-
Antimalarials
-
Antiviral Agents
-
COVID-19 Vaccines
-
Immunoglobulins, Intravenous
-
Immunologic Factors
-
Janus Kinase Inhibitors
-
Spike Glycoprotein, Coronavirus
-
Trace Elements
-
Viral Vaccines
-
Vitamins
-
spike protein, SARS-CoV-2
-
Bevacizumab
-
Nitric Oxide
-
Hydroxychloroquine
-
Chloroquine
-
Interferons
-
Peptidyl-Dipeptidase A
-
ACE2 protein, human
-
Angiotensin-Converting Enzyme 2
-
tocilizumab
-
Zinc
-
sarilumab